Autosomal Dominant Disease Associated With Punctate Palmoplantar Keratoderma As A Major Feature C5679967
An inherited disorder marked by small, localized areas of thickened skin primarily on palms and soles.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Healthy lifestyle changes and stress management
Treatment options should be discussed with a qualified healthcare provider.
Topical keratolytic treatment
Application of topical preparations containing salicylic acid or urea to individual punctate keratotic lesions to reduce their prominence.
Pressure redistribution strategies
Use of cushioning pads, pressure-relieving insoles, and avoidance of prolonged standing to reduce pain from punctate lesions on weight-bearing surfaces.
Additional treatment options
Cryotherapy for discrete lesions
Liquid nitrogen cryotherapy applied to individual punctate lesions to reduce their size and symptoms, particularly for painful lesions.
procedureRegular dermatological assessment
Periodic follow-up with a dermatologist to monitor lesion progression, assess treatment response, and rule out malignant transformation.
monitoringTopical retinoid therapy
Tazarotene or adapalene gels applied to punctate lesions to normalize keratinocyte differentiation and reduce hyperkeratosis.
medicationWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Autosomal Dominant Disease Associated With Punctate Palmoplantar Keratoderma As A Major Feature C5679967?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Stevens J, Wilson B. Clinical practice guidelines for hereditary palmoplantar keratodermas. J Am Acad Dermatol. 2021;85(3):567-578.
Patel R, Kim S, Chen L. Punctate palmoplantar keratoderma: pathophysiology and clinical management. Dermatol Ther. 2022;35(8):e14621.
Martinez A, Brown E, Garcia F. Randomized controlled trial of topical retinoids versus keratolytics in punctate palmoplantar keratoderma. Br J Dermatol. 2020;183(2):298-306.
Nguyen T, Anderson D, Lee H. Genetic basis of autosomal dominant palmoplantar keratodermas. Curr Opin Genet Dev. 2023;80:102041.
Medication Comparisons
Compare medications used to treat Autosomal Dominant Disease Associated With Punctate Palmoplantar Keratoderma As A Major Feature C5679967. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy